Leveraging gold-standard PCR technology, the cobas liat system claims to deliver outcomes in under 20 minutes.

Hoffmann has been vice-chair of Roche since 2006 and a board director since 1996. Among many other roles, he is a trustee of ...

Roche (OTCQX:RHHBY) has received FDA clearance with a CLIA waiver for its cobas liat sexually transmitted infection, or STI, multiplex assay panels. The tests will be available exclusively in the U.S.

The cobas liat test aims to improve patient outcomes by offering rapid, accurate results in decentralized and community-based ...

Roche's core research spans five large areas. Boris Zaïtra, who now leads corporate business development, is confident his team of dealmakers can juggle them.

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

Roche plans to release the system in the US to run tests including vitamin D and steroid assays under CLIA before it possibly receives US Food and Drug Administration clearance.

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in ...

The rise of GLP-1s have made treating obesity one of the largest market opportunities in history. It also has reinforced a ...